momelotinib

In pleasant surprise for GSK, FDA approves Jakafi challenger Ojjaara in broad blood cancer use
In pleasant surprise for GSK, FDA approves Jakafi challenger Ojjaara in broad blood cancer use
Fierce Pharma
GSK
FDA
Ojaara
momelotinib
myelofibrosis
Flag link:
FDA delays approval decision on GSK's $1.9B blood cancer bet
FDA delays approval decision on GSK's $1.9B blood cancer bet
Fierce Biotech
GSK
FDA
momelotinib
blood cancer
Flag link:
Pharma’s Biggest Losses: Once-Dropped Drugs Make Lucrative Comebacks
Pharma’s Biggest Losses: Once-Dropped Drugs Make Lucrative Comebacks
BioSpace
Gilead Sciences
GSK
momelotinib
Roche
Eli Lilly
lebrikizumab
Merck
Zejula
Amgen
Galenica
Veltassa
Cubicin
Flag link:
GSK explores new avenues for JAK drug in $1.9B Sierra buy amid pending FDA decision
GSK explores new avenues for JAK drug in $1.9B Sierra buy amid pending FDA decision
Fierce Biotech
GSK
Sierra Oncology
momelotinib
myelofibrosis
ASH 2022
Flag link:
Was This Acquisition a Smart Move for GlaxoSmithKline?
Was This Acquisition a Smart Move for GlaxoSmithKline?
Motley Fool
GSK
Sierra Oncology
momelotinib
bone marrow cancer
M&A
Flag link:
Sierra doubles down on ex-Gilead drug, deprioritizes other assets
Sierra doubles down on ex-Gilead drug, deprioritizes other assets
Fierce Biotech
Sierra Oncology
myelofibrosis
Gilead Sciences
momelotinib
Flag link:
Sierra Oncology Acquires Gilead’s Stalled Myelofibrosis Drug
Sierra Oncology Acquires Gilead’s Stalled Myelofibrosis Drug
Xconomy
Gilead Sciences
Sierrra Oncology
myelofibrosis
momelotinib
Flag link:
Gilead Fails to Beat Incyte’s Jakafi Drug
Gilead Fails to Beat Incyte’s Jakafi Drug
Investopedia
Gilead Sciences
Jakafi
Incyte
momelotinib
myelofibrosis
Flag link: